Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
3,060,940
CFO
$-501.67 Mln
EBITDA
$-521.22 Mln
Net Profit
$-582.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
| -4.7 | 11.6 | 13.3 | 9.7 | -34.7 | -48.5 | -- |
|
BSE Sensex*
| 3.2 | 1.6 | 7.2 | 9.1 | 14.1 | 21.1 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
| -3.8 | -74.5 | -61.9 | -43.8 | 12.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
|
3.1 | 10.1 | 2.1 | -2.9 | 0.0 | -34.7 | -- | 1.1 |
| 46.7 | 7,725.5 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.4 | 3.8 | |
| 101.5 | 6,652.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.4 | |
| 135.0 | 7,049.6 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 56.9 | 10,905.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.5 | |
| 43.7 | 12,097.3 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.3 | 5.7 | |
| 53.9 | 6,586.2 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.2 | 13.6 | |
| 295.8 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 25.8 | 10,824.9 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.6 | 12,168.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41.7 | 4.8 |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally... administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Riverview II, Cambridge, MA, United States, 02142 Read more
President
Dr. Regina Graul Ph.D.
President
Dr. Regina Graul Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cyclerion Therapeutics Inc (CYCN) stood at $ 11 Mln as on 31-Mar-25
The share price of Cyclerion Therapeutics Inc (CYCN) is $3.07 (NASDAQ) as of 21-May-2025 16:00 EDT. Cyclerion Therapeutics Inc (CYCN) has given a return of -34.69% in the last 3 years.
Cyclerion Therapeutics Inc (CYCN) has a market capitalisation of $ 10 Mln as on 21-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cyclerion Therapeutics Inc (CYCN) is 1.14 times as on 21-May-2025, a 50% discount to its peers’ median range of 2.28 times.
Since, TTM earnings of Cyclerion Therapeutics Inc (CYCN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cyclerion Therapeutics Inc (CYCN) and enter the required number of quantities and click on buy to purchase the shares of Cyclerion Therapeutics Inc (CYCN).
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Riverview II, Cambridge, MA, United States, 02142
The CEO & director of Dr. Regina Graul Ph.D.. is Cyclerion Therapeutics Inc (CYCN), and CFO & Sr. VP is Dr. Regina Graul Ph.D..
There is no promoter pledging in Cyclerion Therapeutics Inc (CYCN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Cyclerion Therapeutics Inc. (CYCN) | Ratios |
|---|---|
|
Return on equity(%)
|
-34.68
|
|
Operating margin(%)
|
0
|
|
Net Margin(%)
|
-141.47
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cyclerion Therapeutics Inc (CYCN) was $0 Mln.
$-0.21
(
